Tdp-43 Pathology
Tdp-43 Pathology - Related Videos
13:31
Novel Atomic Force Microscopy Based Biopanning for Isolation of Morphology Specific Reagents against TDP-43 Variants in Amyotrophic Lateral Sclerosis
0 Views •
Cited by 17 •
2015
Using atomic force microscopy in combination with biopanning technology we created a negative and positive biopanning system to acquire antibodies against disease-specific protein variants present in any biological material, even at low concentrations. We were successful in obtaining antibodies to TDP-43 protein variants involved in Amyotrophic Lateral Sclerosis.
07:07
Measuring Glucose Uptake in Drosophila Models of TDP-43 Proteinopathy
0 Views •
Cited by 3 •
2021
Glucose uptake is increased in Drosophila motor neurons affected by TAR DNA binding protein (TDP-43) proteinopathy, as indicated by a FRET-based, genetically encoded glucose sensor.
07:14
Optogenetic Phase Transition of TDP-43 in Spinal Motor Neurons of Zebrafish Larvae
0 Views •
2022
We describe a protocol to induce phase transition of TAR DNA-binding protein 43 (TDP-43) by light in the spinal motor neurons using zebrafish as a model.
09:20
Perturbing Endothelial Biomechanics via Connexin 43 Structural Disruption
0 Views •
Cited by 6 •
2019
Here, we present a mechanics-based protocol to disrupt the gap junction connexin 43 and measure the subsequent impact this has on endothelial biomechanics via observation of tractions and intercellular stresses.
08:29
Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans
0 Views •
Cited by 7 •
2016
Organized brain cutting procedures are necessary to correlate specific neuropsychiatric phenomena with definitive neuropathologic diagnoses. Brain cuttings are performed differently based on various clinico-academic contingencies. This protocol describes a symmetric bihemispheric brain cutting procedure to investigate hemispheric differences in human brain pathologies and to maximize current and future biomolecular/neuroimaging techniques.
FAQs
Loss of nuclear TDP-43 activity is important because the protein normally supports RNA splicing, transport, and stability. When pathological stress promotes redistribution toward the cytoplasm, these nuclear RNA-processing functions may be reduced while abnormal cytoplasmic material accumulates. This creates a biochemical connection between altered protein localization, disrupted RNA regulation, and neuronal toxicity.
Hyperphosphorylation and ubiquitination represent major biochemical changes in pathological TDP-43. Along with assembly into insoluble aggregates, these modifications distinguish the abnormal protein state from its normal functional condition. Their presence allows investigators to examine how altered protein chemistry accompanies redistribution, impaired RNA regulation, and cellular abnormalities associated with neurodegenerative disease.
Insoluble aggregation indicates that TDP-43 has assembled into a biochemical form different from its normally functioning state. This change is significant because it occurs alongside reduced nuclear RNA-processing activity and cytoplasmic accumulation. Studying solubility and aggregation therefore helps connect altered protein structure with the functional disturbances implicated in neuronal injury.
TDP-43 localization changes can affect RNA regulation by separating the protein from the nuclear environment where it supports splicing, transport, and stability. Cytoplasmic redistribution therefore has consequences beyond protein location alone. It provides a mechanism through which cellular stress and abnormal protein behavior may reduce essential RNA-processing functions in affected neurons.
Biochemical investigation of TDP-43 accumulation, redistribution, modification, and aggregation can support comparisons among neurodegenerative disease subtypes. The pathology is particularly relevant to amyotrophic lateral sclerosis and frontotemporal dementia. Examining these shared protein abnormalities helps researchers characterize disease-related patterns and use them to refine distinctions between clinical or pathological categories.
The abnormal biochemical features of TDP-43 provide targets for biomarker research. Investigators can focus on the protein's redistribution, hyperphosphorylation, ubiquitination, insolubility, or aggregation when seeking disease-associated signals. Such work may help connect molecular changes with neurodegenerative disease and improve the ability to distinguish relevant disease subtypes.
TDP-43 pathology points to several treatment-oriented strategies: promoting abnormal protein clearance, limiting aggregation, or restoring RNA regulation. These approaches address different consequences of the same biochemical disturbance, including insoluble protein accumulation and loss of nuclear function. Their relevance comes from targeting mechanisms linked to neuronal toxicity rather than focusing only on clinical symptoms.